The national health insurance program Medicare is considering plans to extend its coverage to include CAR - T cell therapies . The programme is expected to announce a final decision within the next few months on whether to incorporate the personalised treatment platform , with two CAR - based blood cancer treatments already having been approved by the Food and Drug Administration . Proponents of the plan argue that incorporating the treatments would save money in the long - term , despite their high upfront costs , due to their effectiveness .
The US health insurance program Medicare is considering plans to extend its coverage to include CAR-T cell therapies. The programme is set to announce a final decision within the next few weeks on whether to incorporate the personalised treatment platform, with two CAR-T blood cancer products already having been approved by the Food and Drug Administration. Proponents of the plan argue that incorporating the treatments would save money in the long-term, despite their high upfront costs, due to their effectiveness.